RVL Pharmaceuticals plc CEO Brian Markison's 2019 pay jumps 291% to $4.3M
RVL Pharmaceuticals plc reports 2019 executive compensation
By ExecPay News
Published: April 20, 2020
RVL Pharmaceuticals plc reported fiscal year 2019 executive compensation information on April 20, 2020.
In 2019, four executives at RVL Pharmaceuticals plc received on average a compensation package of $2.2M, a 233% increase compared to previous year.
Average pay of disclosed executives at RVL Pharmaceuticals plc
Brian Markison, Chief Executive Officer, received $4.3M in total, which increased by 291% compared to 2018. 64% of Markison's compensation, or $2.8M, was in stock awards. Markison also received $893K in non-equity incentive plan and $683K in salary.
Tina deVries, EVP, Research & Development, received a compensation package of $1.5M, which increased by 174% compared to previous year. 53% of the compensation package, or $800K, was in stock awards.
Christopher Klein, General Counsel, earned $1.5M in 2019.
James Schaub, Chief Operating Officer, received $1.5M in 2019, which increases by 200% compared to 2018.
Related executives
You may also like
Source: SEC filing on April 20, 2020.